TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06232902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1101
Description: 3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin®
Description: 3mg/kg, single intravenous infusion over 90 min (± 5 min) on first day
Study: NCT04849728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA337
Description: A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA337
Description: A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A total of 1000 patients will be randomised to receive lanifibranor (800 mg/day) or lanifibranor (1200 mg/day), or matching placebo, employing a 1:1:1 randomisation scheme, respectively, without interruption between Part A and Part B.
Study: NCT06261944

Intervention type: DEVICE
Group type: OTHER
Intervention: Near-infrared (NIR)
Description: Near-infrared assessment of glycated keratin in middle fingernail
Study: NCT04981509

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT without contrast

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography with Contrast
Description: Undergo CT with contrast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Fluoride F-18
Description: Given F-18 sodium fluoride
Study: NCT05908175

Intervention type: OTHER
Group type: OTHER
Intervention: FES-assisted gait training
Description: The participants will walk with functional electrical stimulation (and possible body weight support) on a treadmill for 10 weeks, twice a week for 30 minutes.
Study: NCT06178354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryosurgery
Description: Undergo focal cryotherapy ablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound Ablation
Description: Undergo high intensity frequency ultrasound ablation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06255236

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bispectral index (BIS)
Description: * All patient will receive standard monitoring (EKG, Blood pressure, pulse oximetry), and BIS transducer placement at standard frontal area before anesthesia.~* Sedative medication can be given as appropriate.~* Anesthesia induction by inhalation induction with sevoflurane (if intravenous line not presented) or intravenous induction with thiopental 5-6 mg/kg IV~* Other medication including fentanyl 1 mcg/kg IV and cisatracurium 0.1-0.2 mg/kg IV will be given and the patient will be intubated.~* The second BIS will be installed on the bridge of the nose and temporal on the same side as frontal BIS.~* The patient will be maintained with sevoflurane and other anesthetic drugs as appropriate, adjusted per frontal BIS (40-60).~* The frontal BIS and the nasal BIS will be measured until the endotracheal tube is being removed. If the patient has moved until it was impossible to measure the BIS or has any necessity to cancel the BIS measurement. The BIS measurement can be stopped.
Study: NCT06644157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Néo Élite
Description: One session of laser on one side of the face (randomly assigned for each patient for the duration of the study) will be performed every other week for 12 weeks for a total of 6 sessions. All the patients will apply the entire face a sunscreen of sun protection factor 50 with high UVA protection (UV Mune 400; La Roche Posay) during the entire study duration.
Study: NCT06492512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
Description: ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alternate day ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill
Description: ferrous sulfate with an equivalent elemental iron dose of 65 mg per pill every other day
Study: NCT05064124

Intervention type: DEVICE
Intervention: CADDIE - Computer Aided Detection and Diagnosis for Intelligent Endoscopy
Description: 1. CADDIE assisted polyp detection~2. CADDIE assisted polyp characterisation
Study: NCT05747625

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89 Panitumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study: NCT05459688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: 2 mg of CIN-107, once a day for 52 weeks
Study: NCT05959863

Intervention type: DIAGNOSTIC_TEST
Intervention: Captopril Challenge Test
Description: Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.

Intervention type: DIAGNOSTIC_TEST
Intervention: Captopril Challenge Test
Description: Patients received 50 mg captopril orally in the morning after sitting or standing for at least two hours. PAC and PRC were measured using mass spectrometry two hours after administration of capopril.
Study: NCT05309928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: medication administration
Study: NCT05990127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK104
Description: AK104 IV, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tislelizumab
Description: Tislelizumab IV, q3w
Study: NCT06477224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scooter Board Activities
Description: Participants in this arm engage in scooter board activities designed to improve neck control and address dysphagia. These activities include moving the scooter board in various directions using their hands or feet, maneuvering through obstacle courses, and engaging in playful tasks that require reaching or turning, which can enhance neck muscle strength and stability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical Therapy
Description: Participants in this arm receive traditional physical therapy interventions, which might include range-of-motion exercises, muscle strengthening, stretching exercises, and postural control activities. These exercises are aimed at improving overall motor function, with a focus on neck stability and control. Standard physical therapy equipment such as therapy balls, balance boards, and resistance bands may also be used.
Study: NCT05990621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD70 CAR-T cells
Description: 0.6×106/Kg ～ 5.0×106/Kg; cells will be infused intravenously.
Study: NCT06135012

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavitron ultrasonic surgical aspirator (CUSA)
Description: Transection of pancreatic tissue with cavitron ultrasonic surgical aspirator (CUSA).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Scalpel
Description: Transection of pancreatic tissue with scalpel.
Study: NCT06263361

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI imaging
Description: To characterize the peritumoral area in PCNLs through the use of advanced MRI sequences.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cerebral biopsy
Description: To evaluate the predictive value of sodium fluorescence to confirm ex-vivo the diagnostic tumor tissue prior to histopathological examination.
Study: NCT06197295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin with vaginal estrogen cream
Description: Solifenacin 5mg with vaginal conjugated equine estrogen (CEE) 0.625 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination pharmacotherapy
Description: Solifenacin 5mg and Mirabegron 25mg
Study: NCT05602467

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Pulse Stimulation (TPS)
Description: A global brain stimulation approach, which homogenously distributes the total energy of 6000 TPS pulses per session over all accessible brain areas.~Prefrontal, Temporal and Occipital brain areas were stimulated by ultrashort (3μs) ultrasound pulses with typical energy levels of 0.2-0.25 mJ/mm2 and pulse frequencies of 4-5 Hz (pulses per second).
Study: NCT05074173

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Text
Description: These blood pressure values will be automatically uploaded twice daily from a Bluetooth device to a phone application to allow the participant and healthcare team track their blood pressure.
Study: NCT05068895

Intervention type: OTHER
Intervention: liquid chromatography-mass spectrometry
Description: Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.

Intervention type: OTHER
Intervention: liquid chromatography-mass spectrometry
Description: Metabolomics is a rapidly evolving high-throughput technology that allows the measurement of the entire complement of metabolites generated by biochemical reactions under certain conditions in biological fluids or tissues. This technology has been used extensively to identify biomarkers in various cancers, nervous system diseases, cardiovascular diseases, pituitary diseases, and other diseases. The identification of biomarkers can be clinically useful for a more accurate diagnosis, prognosis, and treatment choice as well as disease monitoring. Among mass spectrometry (MS) methods, liquid chromatography-mass spectrometry (LC-MS) has been recognized as a robust metabolomics tool and has been widely applied in metabolite identification and quantification due to its high sensitivity, peak resolution, and repro- ducibility.
Study: NCT04876053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Food Delivery Intervention
Description: Each weekly food box will include \~9,000 calories of food, equivalent to the amount the average household receives prorated per week from an average Arkansas food pantry. The boxes will be designed by a registered dietitian. The boxes will follow ADA's Create Your Plate method consistent with the meal pattern promoted in the American College of Physicians (ACP) DSMES. The foods will also reflect Feeding America's Detailed Foods to Encourage framework, developed by nutrition experts and food bank staff to represent USDA dietary guidelines with healthy food that can be made available by food banks.
Study: NCT06072807

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain Imaging with 18F-FES
Description: Using 18F-FES radiotracer in PET/CT scan to evaluate brain metastases in ER positive breast cancer patients.
Study: NCT06411756

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Narrative videos
Description: Culturally targeted narrative videos will be sent via email.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A Fitbit activity tracker
Description: A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: A Fitbit activity tracker
Description: A Fitbit activity tracker is a wireless wearable device that monitors physical fitness activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Daily text message
Description: A daily adaptive step goal that will be sent via text message with a short positive message.

Intervention type: OTHER
Group type: OTHER
Intervention: Monthly Zoom meeting
Description: Monthly Zoom meetings, led by the research team, to discuss physical activity with other study subjects.

Intervention type: OTHER
Group type: OTHER
Intervention: Website access
Description: Access to Physical Activity Centers Empowerment (PACE) website.

Intervention type: OTHER
Group type: OTHER
Intervention: Printed materials
Description: Printed materials from the American College of Sport's Medicine's Moving through Cancer campaign.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Printed materials
Description: Printed materials from the American College of Sports Medicine's Moving through Cancer campaign.
Study: NCT06134362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAB LA
Description: Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).
Study: NCT05378347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Endurant II or Endurant IIs Stent Graft System
Description: EVAR treatment with Medtronic Endurant II/IIs Stent Graft System

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis
Description: EVAR treatment with Excluder / Excluder Conformable Stent Graft System
Study: NCT06501729

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kiss
Description: Participants will kiss with their partners for 40 seconds. The kiss will be on the mouth.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kiss
Description: Participants will kiss with their partners for 40 seconds. The kiss will be on the mouth.
Study: NCT05522868

Intervention type: DRUG
Group type: OTHER
Intervention: SB17170
Description: SB17170 capsules, Oral administration 21days/cycle
Study: NCT05156125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX002
Description: Dose A tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VTX002
Description: Dose B Tablet administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablet for VTX002 administered orally once daily
Study: NCT05509192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPI
Description: Patients from both study groups will receive premedication in the usual fashion, typically 0-2 mg of IV midazolam at the discretion of the care team. Patients in both study groups will receive 1 mg/kg of lidocaine intravenously, followed by an opioid such as fentanyl (1-2 mcg/kg), prior to administration of induction drugs. Patients assigned to MTPI will then be given rocuronium (0.6mg/kg), followed by propofol intravenously as a single bolus within 10 seconds. A typical propofol bolus for induction ranges from 1-2mg/kg, depending on the patient's age, medical history, and co-morbidities. Propofol dosing will be at the discretion of the care team. Patients will count down from one hundred. Once apnea occurs, as indicated by a lack of respiratory effort, the eyes will be taped, and intubation with C-MAC (Karl Storz 8403ZX, Tuttlingen, Germany) is initiated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic Induction
Description: Patients assigned to CI will be induced as per routine care using lidocaine 1 mg/kg, an opioid such a fentanyl (1-2 mcg/kg), propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg, and the intubation will be performed with a C-MAC. Patients will also count down from one hundred. The medications used for induction of anesthesia in both arms of the study are those used for routine anesthesia care. In both study arms, dosing of medications for induction of anesthesia is standardized (lidocaine 1 mg/kg, fentanyl 1-2 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg). The only difference between the two arms will be the timing of the medication administration, and the order in which medications are administered. The documentation of induction and intubation will be the same as that of the MTPI group. Vital signs and other parameters will continuously be recorded in the intraoperative record. Emergence and extubation are not protocolized.
Study: NCT06238921

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiation
Description: Stereotactic Radiation to intact brain metastases or post-operative cavity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: One week +/- 4 days following receipt of SRS, zimberelimab 360 mg IV will be administered. This will be followed by zimberelimab 360 mg IV every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan
Description: SG will be administered on days 1 and 8 (10 mg/kg) of 21 day treatment cycles. This will be one week +/- 4 days following receipt of SRS for the first dose.
Study: NCT06412198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adagrasib
Description: Given by PO
Study: NCT05848375

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic rotator cuff repair
Description: The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic rotator cuff repair
Description: The operation involves systematic acromioplasty during the supra +/- infraspinatus repair and sometimes requires a tenotomy of the long biceps if it is pathological.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA associated to GA)
Description: Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance associated to General Anesthesia performed by injection of diprivan and ultiva.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naropeine or chirocaine (Arthroscopic rotator cuff repair under LRA)
Description: Loco Regional Anesthesia is performed by injecting anesthetic (between 10 and 20 ml of naropeine or chirocaine) into the interscalene nerve block under ultrasound guidance
Study: NCT05522868

Intervention type: DRUG
Group type: OTHER
Intervention: SB17170
Description: SB17170 capsules, Oral administration 21days/cycle

Intervention type: DRUG
Group type: OTHER
Intervention: SB17170
Description: SB17170 capsules, Oral administration 21days/cycle

Intervention type: DRUG
Group type: OTHER
Intervention: SB17170
Description: SB17170 capsules, Oral administration 21days/cycle

Intervention type: DRUG
Group type: OTHER
Intervention: SB17170
Description: SB17170 capsules, Oral administration 21days/cycle
Study: NCT06481436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of ChatGPT
Description: Patients will be provided with the opportunity to ask ChatGPT questions about their primary presenting problem at a time point during their initial Urogynecology consultation visit.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of ChatGPT
Description: Patients will be provided with the opportunity to ask ChatGPT questions about their primary presenting problem at a time point during their initial Urogynecology consultation visit.
Study: NCT05644561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Description: Ravulizumab will be administered by intravenous (IV) infusion.
Study: NCT06064877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for this study will be normal saline